Alterity Therapeutics Limited (NASDAQ:ATHE – Get Free Report) saw a large increase in short interest in the month of April. As of April 15th, there was short interest totalling 90,300 shares, an increase of 290.9% from the March 31st total of 23,100 shares. Based on an average daily volume of 82,300 shares, the days-to-cover ratio is currently 1.1 days. Approximately 1.1% of the company’s shares are short sold.
Alterity Therapeutics Stock Down 3.0 %
Shares of NASDAQ ATHE opened at $2.26 on Friday. The company has a fifty day moving average price of $1.95 and a 200 day moving average price of $2.18. Alterity Therapeutics has a 1-year low of $1.55 and a 1-year high of $5.41.
Wall Street Analyst Weigh In
Separately, Benchmark reissued a “speculative buy” rating and set a $4.00 price objective on shares of Alterity Therapeutics in a research note on Thursday, March 7th.
About Alterity Therapeutics
Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson's disease.
Read More
- Five stocks we like better than Alterity Therapeutics
- How to Calculate Inflation Rate
- Semiconductor Shakeout: Finding Potential Amidst Turmoil
- Stock Average Calculator
- Hasbro’s Management Made All the Right Calls This Quarter
- How to Choose Top Rated Stocks
- Caterpillar’s Market Reset Isn’t Over: Get Ready for Lower Prices
Receive News & Ratings for Alterity Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alterity Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
